TriSalus officer sells shares to cover tax withholding

TriSalus Life Sciences, Inc. executive Jodi Devlin, Chief of Clinical Operations, reported three transactions in common stock.

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. executive Jodi Devlin, Chief of Clinical Operations, reported three transactions in common stock. Across 3,207 shares, stock was sold at prices between $4.09 and $4.13 per share to satisfy tax withholding obligations tied to previously vested restricted stock units. A footnote explains these sales were made solely to cover taxes and were not discretionary. Following the most recent transaction, Devlin directly holds 97,364 shares of TriSalus common stock.

Insider Trade Summary

Net Seller: 3,207 shares

Net Sell 3 txns

Insider Devlin Jodi

Role Chief of Clinical Operations

Sold 3,207 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	273	$4.12	$1K
Sale	Common Stock	1,772	$4.09	$7K
Sale	Common Stock	1,162	$4.13	$5K

Holdings After Transaction: Common Stock — 97,364 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did TriSalus Life Sciences (TLSI) report for Jodi Devlin?

TriSalus Life Sciences reported that Chief of Clinical Operations Jodi Devlin sold shares of common stock in three transactions. These sales were made to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units, and were not discretionary trades in the open market.

How many TriSalus (TLSI) shares did Jodi Devlin sell and at what prices?

Jodi Devlin sold a total of 3,207 shares of TriSalus common stock. The transactions occurred at per-share prices of $4.09, $4.12, and $4.13, according to the Form 4, and were linked to tax withholding on vested restricted stock units.

Why were Jodi Devlin’s TriSalus (TLSI) share sales executed according to the Form 4?

The Form 4 states that the reported share sales represent stock sold to satisfy tax withholding obligations associated with the vesting of restricted stock units. The footnote clarifies that these transactions do not represent discretionary sales by Jodi Devlin in the open market.

How many TriSalus (TLSI) shares does Jodi Devlin own after these transactions?

After the reported tax-related sales, Jodi Devlin directly holds 97,364 shares of TriSalus Life Sciences common stock. This post-transaction holding figure is disclosed in the Form 4 as the number of shares beneficially owned following the most recent transaction date.

Are Jodi Devlin’s recent TriSalus (TLSI) transactions considered routine tax withholding events?

Yes. The Form 4 footnote explains that the sales were executed to cover tax withholding obligations from restricted stock units vesting. This characterization indicates the activity is compensation-related and non-discretionary, rather than a voluntary decision to reduce equity exposure in TriSalus shares.

Do the Form 4 filings show any TriSalus (TLSI) option exercises or derivative trades by Jodi Devlin?

No derivative transactions are listed for Jodi Devlin in this Form 4. The derivative summary is empty, indicating no reported option exercises, warrant exercises, or other derivative conversions alongside these tax-related common stock sales during the disclosed period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:25 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devlin Jodi

(Last) (First) (Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER COLORADO 80031

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief of Clinical Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S		1,162(1)	D	$4.13	99,409	D
Common Stock	03/12/2026		S		1,772(1)	D	$4.09	97,637	D
Common Stock	03/16/2026		S		273(1)	D	$4.12	97,364	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the reporting person. This transaction does not represent a discretionary sale by the reporting person.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)